Table 3. Dose-Response Analysis for the Composite Analysis and Individual Outcomes of SRD, RVO, and ION Associated With PDE5I Use.

Outcome and No. of PDE5I prescriptions	Adjusted IRR (95% CI)a
Overall
<5	1.74 (1.10-6.77)
≥5	2.90 (1.15-3.81)
SRD
<5	1.73 (1.14-2.64)
≥5	1.90 (1.41-2.55)
RVO
<5	3.30 (1.48-7.38)
≥5	2.39 (1.38-4.14)
ION
<5	1.25 (0.70-2.21)
≥5	1.55 (1.00-2.40)

Abbreviations: ION, ischemic optic neuropathy; IRR, incidence rate ratio; PDE5I, phosphodiesterase type 5 inhibitor; RVO, retinal vascular occlusion; SRD, serous retinal detachment.

^a Compared with nonuse of PDE5Is.